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Polysensitivity is defined as 3 or more positive patch test reactions. The role of Filaggrin loss of function 
mutations in patients with polysensitivity has not been studied when barrier bypass and possible preceding 
barrier damage was excluded.  
Methods 
169 Patients with 3 or more, non-cross reacting, positive patch test reactions were prospectively enrolled in this 
study. Exclusion criteria were a history of hand dermatitis, nickel and metal implants and stasis dermatitis. 
Subjects were patch tested to the North American extended patch test series as well as relevant other haptens. 
DNA was obtained and sequenced for the following Filaggrin (FLG) loss of function mutations (R501X, 
2282del4, R2447X and S3247X). 
Results 
165 patients were genotyped for the four FLG mutations. There is a significant association between R501X 
mutations and polysensitivity.  For the other 3 tested mutations, there was no significant association with 
polysensitivity. When all mutations are combined, there was a significant association between loss of function 
FLG mutations and polysensitivity in patients with a history of atopic dermatitis.  
Conclusion 
When skin barrier bypass is excluded there is a significant association between polysensitivity and FLG loss of 
function mutations.  
Keywords. Polysensitivity, contact dermatitis, skin barrier, Filaggrin, loss of function mutations 
 
 










1.  Introduction 
Polysensitivity has been defined as the three or more positive patch tests.
1
 Patients with atopic dermatitis or 
other forms of eczema are more likely to develop polysensitivity. This suggests that defects in barrier function 
as caused by null mutations in Filaggrin (FLG) or other induced defects in barrier function may play a 
predisposing role. Patients with chronic leg ulcers are also prone to polysensitivity.
2,3
  In a study involving 163 
individuals with polysensitivity 13 were found to have null mutations in FLG (R501X or 2282del4) but this 
finding was not significant.
4
  The role of loss of function mutations in FLG in contact dermatitis is 
controversial. Most studies examining this have focused on this relationship in hand dermatitis with conflicting 
results.
4-6
 Barrier dysfunction from gene mutations, besides FLG, have also been described.  Molin et al 
reported an association between allergic contact dermatitis on the hands and combined deletions in genes 




In this Canadian study, we evaluated the predisposing role of FLG loss of functions mutations in 
polysensitivity. We have attempted to exclude any subjects who would have a high likelihood of confounding 
owing to sensitization through skin barrier bypass; this includes prior hand dermatitis, where damage to the skin 
barrier could allow easier penetration and so promote the development of multiple sensitivities.   
 
2.  Methods 
Patients (n=169) were recruited prospectively (2009 to 2017) from 4 Canadian University based patch test 
clinics (Universities of Saskatchewan [PRH] and Ottawa [MP], Ontario, McGill University [DS], Quebec and 
Dalhousie University [PRH]), Nova Scotia. Saskatchewan is in Western Canada and Nova Scotia is in the East. 
Ottawa and Montreal are situated geographically in closer proximity. The provinces of Nova Scotia and 
Saskatchewan have populations of only 1 million while the cities of Ottawa and Montreal have populations over 
one million each.  
 










All patients were patch tested on day 0 (D0) to the North American extended series of at least 65 haptens or 
with the North American Contact Dermatitis Group series of 70 allergens along with additional testing 
depending on the clinical presentations. The patches were removed on D2 and read again on day D4 or D5. For 
some haptens the result was again read between D5 and D10. Patch test material was acquired from 
Chemotechnique Diagnostics (Vellinge, Sweden) or from AllergEAZE (SmartPractice, Calgary, Canada) and 
applied using either Finn Chambers (SmartPractice) or IQ Ultra (Chemotechnique Diagnostics) and Scanpore 
tape (Norgesplaster, Vennesla, Norway). Methods for patch testing, evaluation of reactions and data recording 




Patients with 3 or more positive patch tests were included in this study. Haptens known to cross-react such as 
formaldehyde and formaldehyde releases were counted as a single positive for the purpose of inclusion.  In 
order to exclude skin barrier bypass from piercings, positive reaction to nickel was not counted as one of the 3 
positive reactions and patients with metal implants were excluded.  As irritant contact dermatitis and 
occupational related dermatitis mostly involve hand dermatitis, we excluded patients with a prior history of 
hand dermatitis. In addition, patients with a history of stasis dermatitis, with and without ulceration, were 
excluded.  
 
Genomic DNA was extracted from blood or saliva samples and genotyped for the following prevalent European 
FLG null mutations: R501X, 2282del4, R2447X and S3247X. FLG genotyping was performed by a core facility 
(DNA Sequencing and Services, University of Dundee, Dundee, United Kingdom) as well as at Dalhousie 
University. As the prevalence of these mutations is not known for other ethnic groups in Canada, the study was 
confined to those with self-identified European ancestry. The control population (n=891) were adult caucasian 
volunteers from Toronto, Ontario, whose DNA is commercially available (The Centre for Applied Genomics, 
Ontario Population Genomics Platform [OPGP], Toronto, Ontario, Canada). The control population was 
previously used in genetic studies of FLG loss of function mutations and genotyped for the same FLG 
mutations.
10
 The age of this cohort ranged from 23 to 77 with 68.5% being female.  As this is a general 










population sample, the presence or absence of coexisting atopic dermatitis is not known. This control 
population has not been patch tested. 
 
The association between FLG loss of function mutations and polysensitivity was performed using X
2
-test and 
logistic regression analysis. A P-value of ≤ 0.05 was considered significant. All statistical analyses were 
performed using Stata Statistical Software: Release 15. College Station, Texas and SAS STAT 14.3 version 9.4 
(SAS Institute, Cary, North Carolina).  Institutional approval from the ethics review boards was obtained for 
each of the institutions directly involved with patient recruitment and informed consent was obtained from each 
of the participants.  
 
3.  RESULTS 
A total of 169 patients met the inclusion and exclusion criteria, respectively, and were enrolled in this study. 
Four patients were subsequently excluded due to DNA low quality. 60 patients were recruited in Saskatchewan, 
45 from Quebec, 42 from Ontario, and 16 from Nova Scotia. The mean age was 52 years with an age range 
from 10 to 89 years with only 4 patients below the age of 20 years.  The majority of the patients was female 
(72%). About one third reported a history considered by the dermatologist as being consistent with atopic 
dermatitis, being a history of eczema starting in childhood and with a predominant flexural distribution. A self-
reported family history of atopic dermatitis was recorded in 62 patients (37%). Asthma was reported in 37 
patients (22%), hay fever in 64 patients (38%) and food allergies in 30 patients (18%) (Table 1).  
 
FLG genotypes were obtained for all 165 patients. Null mutations were identified in 28 patients (17%) (Table 
2). Single FLG mutations (heterozygous) were found in 24 patients (15%). Two patients were homozygous (one 
for R501X and the second for 2284del4). Two patients had 2 different mutations (compound heterozygous) one 








.   Patients homozygous or 
compound heterozygous for FLG mutations were more likely to be younger, to have a personal history of atopic 
dermatitis, asthma, and food allergies, than those with heterozygous mutations or wild type FLG (Table 1). 










They are also more likely to have a family history of asthma but not atopic dermatitis. The face and neck were 
more commonly affected by dermatitis in the mutant FLG genotype (Table 1). 
 
There was a significant association between R501X mutations and polysensitivity with an R501X mutation in 
8.5% (N=14) of patients and 4% (N=34) in the controls (X
2 
test: P = 0.008).  The odds of having a R501X 
mutations in the patients was 2.33 times higher than in the controls, Odds Ratio of 2.33 (95% CI: 1.13 to 4.59).  
For the other 3 tested mutations (2282del4, R2447X and S3247X) there was no significant association with 
polysensitivity. When all mutations are combined, a significant association with polysensitivity persists with 28 
(17%) of the patients having a mutation compared to 11% in the controls (X
2 
P-value=0.030). The odds ratio of 
the combined mutations was 1.65 (95% CI 1.05 to 2.61) for the patients compared to the controls.  The 
proportion of FLG mutations increased with the number if positive patch tests (Table 3). 
 
The 20 commonest reacting haptens are shown in Table 4. There were no significant differences in odds ratios 
when those with FLG loss of function mutations are compared to those without mutations.  Owing to low 
counts there was insufficient power to perform multivariate analysis to adjust for atopic dermatitis and gender.  
 
4.  Discussion 
In order to elicit cell-mediated hypersensitivity in allergic contact dermatitis, the allergen/hapten must penetrate 
the epidermal barrier constituted by both the fully keratinized stratum corneum matrix as well as the scaffold 
proteins of tight junctions.
11
 Damage to the barrier either by a prior irritant dermatitis or eczema enhances 
absorption and facilitates an allergic response. Whether genetic modifications in the skin barrier predispose to 
allergic contact dermatitis has been debated. A major contributor to cutaneous barrier integrity is filaggrin and 
its breakdown components.
12
  Null mutation in FLG are associated with increased permeability which would 
allow allergens to more easily cause sensitization. Such mutations are a major predisposing factor in atopic 
dermatitis.
13
 Their role in allergic contact dermatitis is less clear. Loss of function mutations in FLG have been 
associated with irritant dermatitis
14-17
 which in turn would damage barrier function and predispose to allergic 












 This is supported by data that shows that loss of functions mutations in FLG in 
association with dermatitis, increases the likelihood of contact sensitization while the presence of FLG 
mutations without dermatitis had no influence
19
.   Landeck et al 
20
 showed no remarkable differences in contact 
sensitization in patients with FLG mutations compared to those having wild type FLG and similarly Carlsen et 
al found no significant association between allergic contact dermatitis and FLG.
4
 However, it should be noted 
that the Landeck study used a cohort of occupational hand dermatitis patients, which may explain the lack of 
association.  It has been previously suggested that the size of most haptens is small making them able to 




It is difficult to study the contribution of FLG loss of function mutation without attempting to eliminate other 
causes of barrier dysfunction or barrier bypass. Most potent allergens are also potent irritants.
21
  Nickel, the 
most common patch test positive seen,
8
 has not been associated with FLG mutations,
22
 but this could have been 
due to the frequency of piercings in the population.  In this study, we have attempted to avoid confounding 
factors in evaluating the role of FLG null mutations and contact sensitivity. We have shown that in patients 
referred with a possible contact dermatitis at sites other than the hands there is an association between FLG 
mutations and multiple contact sensitivities. This association was significant in those individuals with a self-
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Table 1. Demographics and Sites affected stratified by FLG genotype.  
 
Demographics no FLG Mutations (N=137) FLG Mutations (N=28) 
Female 74% (101) 62% (18) 
Average age 54 (SD 15.06)  
 
46 (SD 17.24) 
Atopic Dermatitis 31% (43) 43% (12) 
Asthma 20% (27) 29% (8) 
Hay fever 37% (51) 36% (10) 
Food allergies 16% (22) 14% (4) 
Family History of Atopic Dermatitis 34% (47) 46% (13) 
Family History of Asthma 33% (45) 29% (6) 
Family History of Food Allergies 16% (22) * 15% (3) ** 
Sites affected    
Head and Neck 34% (56) 45% (10) 
Widespread 22% (36) 25% (6) 
Multiple Sites 13% (21) 13% (3) 
Trunk 8% (13) 17% (4) 
Feet and Legs 7% (11) 0 
Arms 2% (3) 0 
Intraoral 1% (2) 4% (1) 
* and ** Family history of food allergy not recorded in 24 cases and 8 cases respectively.  


















Table 2. Genotyping results and statistical analysis of filaggrin loss-of-function mutations in patients with polysensitivity (N=165), polysensitivity 
without a history of atopic dermatitis (N=110) and Canadian controls (N=891).  
FLG Genotype All Patients (N=165)  Controls (N=891) Patients without Atopic Dermatitis (N=110) 
Wild Type 137 793 94 
All Mutations 28 98 16 
Proportion with FLG Null Mutations 17% 11% 14.5% 
X
2 
P =0.0299 P = 0.269 
Odds Ratio (95% CI) 1.65 
(1.05 to 2.61) 
    1.38    





















































No FLG Mutations 87 58 35 23 
FLG Mutations 20 16 10 9 
Percentage of FLG Mutations 18.7% 21.6% 22.2% 28.1% 










Table 4. Association between Filaggrin mutation carrier status and positive contact reaction to the 20 commonest haptens giving positive reaction in 
this study.   
  All Cases (N=165) 
  Wild Type (N=137) Mutant (N=28)   OR (95% CI) P-Value 
Fragrance mix I 53 (38%) 7 (25%) 0.53 (CI 0.21, 1.35) 0.19 
Myroxylon pereirae 30 (22%) 9 (32%) 1.66 (CI 0.67, 4.10) 0.27 
Fragrance mix II 14 (10%) 4 (14%) 1.52 (CI 0.45, 5.08) 0.50 
Colophony 24 (18%) 5 (18%) 0.89 (CI 0.30, 2.64) 0.83 
Cinnamic aldehyde 15 (11%) 2 (7%) 0.59 (CI 0.54, 4.22) 0.50 
Formaldehyde 34 (25%) 9 (32%) 1.39(CI 0.57, 3.38) 0.47 
Quaternium 15 32 (23%) 8 (29%) 1.40 (CI 0.56, 3.51) 0.48 
Diazolidinyl urea 11 (8%) 2 (7%) 0.92 (CI 0.19, 4.44) 0.91 
Cobalt 24(18%) 9(32%) 2.19(CI 0.88, 5.46) 0.094 
Nickel   25 (18%) 5 (18%) 1.28 (CI 0.42, 3.94) 0.67 
Methylisothiazolinone 15 (11%) 1 (4%) 0.34 (CI 0.042, 2.79) 0.32 
Lanolin 23 (17%) 8 (29%) 1.98 (CI 0.74, 5.28) 0.17 
P-phenelenediamine 22 (16%) 4 (14%) 1.09 (CI 0.33, 3.60) 0.89 
Carba mix 10 (7%) 4 (14%) 1.97 (CI 0.56, 6.89) 0.94 
Iodopropynylbutyl carbamate 13 (9%) 3 (11%) 1.01 (CI 0.26, 3.91) 0.99 
Thiuram mix 14 (10%) 2 (7%) 0.69 (CI 0.15, 3.24) 0.63 
Propolis 13 (9%) 2 (7%) 0.62 (CI 0.13, 3.00) 0.55 
Bacitracin 28 (20%) 3 (11%) 0.44 (CI 0.12, 1.58) 0.21 
Neomycin 23 (17%) 5 (18%) 1.27 (CI 0.42, 3.83) 0.68 
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